Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. by Young, RJ et al.
Predictive and prognostic factors associated with soft tissue sarcoma 
response to chemotherapy: a subgroup analysis of the European 
Organisation for Research and Treatment of Cancer 62012 study 
Robin Young1, Saskia Litiere2, Michela Lia2, Pancras Hogendoorn3, Cyril Fisher4, Gunhild 
Mechtersheimer5, Soren Daugaard6, Rafael Sciot7, Francoise Collin8, Christina Messiou4, Viktor 
Grunwald9, Alessandro Gronchi10, Winette van der Graaf11, Eva Wardelmann12, Ian Judson4 
1 – Weston Park Hospital, Sheffield, UK 
2 – EORTC Headquaters, Brussels, Belgium 
3 – Leiden University Medical Centre, Leiden, Netherlands 
4 – Royal Marsden Hospital, London, UK 
5 – University Hospital Heidelberg, Heidelberg, Germany 
6 – University of Copenhagen, Copenhagen, Denmark 
7 – U.Z. Leuven, Leuven, Belgium 
8 – Centre Georges Francois Leclerc, Dijon, France 
9 – Medizinische Hochschule Hanover, Hanover, Germany 
10 – Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy 
11 – Radboud University Medical Centre, Nijmegen, Netherlands 
12 – University Hospital Munster, Munster, Germany 
Corresponding author: r.j.young@sheffield.ac.uk 
  
Introduction 
Soft tissue sarcomas (STS) are a group of rare aggressive tumours of mesenchymal origin, separated 
into over 50 different subtypes by histological and molecular classifications. Chemotherapy is the 
mainstay of treatment for patients with unresectable metastatic disease, and is usually administered 
with palliative intent. Doxorubicin and ifosfamide have single-agent activity in STS [JCO 1995 
13:1537-45, EJC 2002 38:2397-406], but the role of combination doxorubicin-ifosfamide has been 
less certain. The European Organisation for Research and Treatment of Cancer (EORTC) 62012 study 
was a multi-centre randomised phase III trial of first-line single-agent doxorubicin vs intensified 
doxorubicin-ifosfamide chemotherapy for young, fit patients with advanced intermediate or high 
grade STS [Lancet Oncol 2014 15:415-23]. Combination chemotherapy was associated with a 
significantly higher tumour response rate (complete + partial response, 26% vs 14%; p<0.0006) and 
improved progression free survival (PFS, hazard ratio (HR) 0.74, 95% confidence intervals (CI) 0.60 – 
0.90; p=0.003), but overall survival (OS) was not significantly different (HR 0.83, 95% CI 0.67 – 1.03; 
p=0.076). Furthermore, combination chemotherapy was associated with significantly more toxicity 
(Grade 3-4 febrile neutropenia 46% vs 13%; p<0.0001). The study authors concluded that single-
agent doxorubicin was appropriate for the majority of patients with advanced STS, however 
combination chemotherapy was justified for selected patients in whom the primary aim of 
treatment was tumour shrinkage, to alleviate symptoms or to enable local disease control by 
subsequent surgery or radiotherapy. 
A previous meta-analysis of seven heterogeneous EORTC-led clinical trials of first-line anthracycline-
based chemotherapy for advanced STS reported younger age, good performance status (PS) and 
absence of liver metastases as prognostic of both improved tumour response to chemotherapy and 
OS [JCO 1999 17:150-7]. High tumour grade and liposarcoma histology were other factors associated 
with improved tumour response to chemotherapy, whilst low tumour grade and increased time 
between initial sarcoma diagnosis and commencing first-line palliative chemotherapy were 
associated with improved OS.  
We performed a subgroup analysis of the EORTC 62012 study to validate factors prognostic of 
tumour response to chemotherapy and OS in patients with advanced STS treated in a contemporary 
prospective randomised phase III clinic trial. We then explored tumour histology and tumour grade 
as predictive factors to identify patient subtypes more likely to benefit from treatment with 
combination chemotherapy. 
  
Methods 
Patients included in the subgroup analysis: 
455 patients were recruited to the EORTC 62012 study. The detailed eligibility criteria for the EORTC 
62012 study have previously been published [Lancet Oncol 2014 15:415-23], including age  ≤60 
years, WHO performance status (PS)  0 or 1, intermediate or high grade by local pathology opinion. 
Patients who received at least one cycle of chemotherapy were eligible for the subgroup analysis. A 
central pathology review of histology and tumour grade was performed by six expert STS 
pathologists. Cases without central pathology review were excluded from the subgroup analysis. 
Patients without sarcoma histology, or where tumour grade was low or not assessable by central 
pathology review, were also excluded from the subgroup analysis. Patients who did not meet other 
eligibility criteria for the main study were also excluded (figure 1). The subgroup analysis study 
population consisted of 310 patients with similar characteristics to the main study population (table 
1). 
Gender, age, PS, time from first presentation with sarcoma to starting palliative chemotherapy, 
tumour grade, histological subtype, and sites of metastases were assessed as potential predicitve 
factors  for tumour response to chemotherapy and their relationship to prognosis, i.e. OS. Patients 
were included in the analysis based on central pathology review. Histological subtype and tumour 
grade were then assessed as factors predictive of improved tumour response and OS with 
combination chemotherapy. In this exploratory analysis, histological subtype and tumour grade were 
analysed according to local and central pathology assignment. 
Statistics: 
Prognostic factor analyses were performed using univariate logistic regression models for tumour 
response to chemotherapy, and cox regression models for OS. Factors included in the final 
multivariate models were identified using a reduced stepwise selection procedure. A significance 
level of 0.15 was required to include a factor within the multivariate model, and a significance level 
of 0.05 was required for a factor to stay in the model.  
  
Results 
Central pathology review of tumour histology was available for 354/455 cases (78%). Discordance 
with local assessment was observed in 118 cases (33%), including six patients who did not have STS 
histology on central review. Central pathology review of tumour grade was available for 339/455 
cases (75%). Discordance with local assessment was observed in 141 cases (42%). After excluding 
patients that failed other eligibility criteria, 310 patients were included in the subgroup analysis. 
Consistent with the main study results, combination chemotherapy was associated with improved 
tumour response (odds ratio (OR) 2.44, 95% CI 1.38 – 4.31; p=0.002), but OS was not significantly 
different (HR 0.82, 0.63 – 1.06; p=0.128).   
In multivariate analysis, gender, age, PS, time from first presentation with sarcoma to starting 
palliative chemotherapy, tumour grade, histological subtype, and sites of metastases were assessed 
as potential factors predictive of tumour response to chemotherapy and improved OS. Central 
pathology review of histology and tumour grade were used for this analysis. 
Patients with liposarcoma had improved tumour response to chemotherapy compared to other 
histological subtypes (p=0.014), whilst patients with metastases other than lung, liver or bone had a 
poorer tumour response (OR 0.42, 95% CI 0.23 – 0.78; p=0.006) (table 2). Patients with high grade 
tumours had an improved tumour response to chemotherapy, but this was not statistically 
significant (OR 1.43, 95% CI 0.76 – 2.67). Liposarcoma and other metastatic disease sites were 
retained as factors predictive of tumour response to chemotherapy in the final multivariate model.  
PS 1 (HR 1.37, 95% CI 1.06 – 1.77; p=0.017), shorter time to palliative chemotherapy from initial STS 
presentation (HR 1.49, 95% CI 1.08 – 2.07; p=0.014), and presence of bone metastases (HR 1.44, 95% 
CI 1.00 – 2.07; p=0.052) were associated with reduced OS (table 3). In the final multivariate model, 
only bone metastases remained statistically significant (HR 1.56, 95% CI 1.16 – 2.09; p=0.003).  
Tumour grade and histological subtype, grouped into liposarcoma, leiomyosarcoma, synovial 
sarcoma, undifferentiated pleomorphic sarcoma (UPS), or ‘other’, were assessed as predictive 
factors. Outcomes differed dependent on local or central pathology assignment of histological 
subtype (table 4). By local pathology assessment of histology, synovial sarcomas and ‘other’ 
subtypes had a higher response rate (complete + partial response) with combination chemotherapy 
compared to single-agent doxorubicin (43.5% vs 11.1% (OR 6.15, 95% CI 1.43 – 26.39) and 29.0% vs 
10.5% (OR 3.48, 95% CI 1.27 – 9.53) for synovial sarcoma and ‘other’ respectively), whilst tumour 
response rates for liposarcoma, leiomyosarcoma and UPS subtypes did not differ significantly by 
treatment arm. In contrast, by central pathology assessment, the UPS subtype had a higher response 
rate with combination chemotherapy than with single-agent doxorubicin (42.3% vs 6.9% (OR 9.90, 
95% CI 1.93 – 50.7)), but response did not differ significantly between treatment arms for 
liposarcoma, leiomyosarcoma, synovial sarcoma or ‘other’ subtypes. Analysis of OS by local 
pathology assessment showed no interaction between histological subtype and treatment arm, 
whilst patients with UPS by central pathology review had improved OS with combination 
chemotherapy compared with single-agent doxorubicin (HR 0.44, 95% CI 0.26 – 0.79) (figure 2),.  
Irrespective of local or central pathology assessment, high grade tumours had an improved response 
rate with combination chemotherapy compared with single-agent doxorubicin (OR 2.93, 95% CI 1.30 
– 6.61 and 3.64, 95% CI 1.72 – 7.70 by local and central pathology assessment respectively). 
Response rate in intermediate grade tumours by either local or central pathology assessment did not 
differ significantly by treatment arm. No interaction between treatment arm and tumour grade was 
identified in OS analysis, irrespective of local or central pathology assessment of grade. 
  
Discussion 
We observed a substantial discordance between local pathology assessment and central pathology 
review of histological subtype and tumour grade. This degree of discordance is consistent with levels 
reported by other STS studies [Lancet Oncol 2012 13(10):1045-54; Br J Cancer 1991 64(2):315-20; 
JCO 1989 7(12):1845-551; JCO 1986 4(11):1658-61]. Sarcoma. 2014;2014:686902. doi: 
10.1155/2014/686902. Epub 2014 Aug 5.Histopathological diagnostic discrepancies in soft tissue 
tumours referred to a specialist centre: reassessment in the era of ancillary molecular 
diagnosis.Thway K1, Wang J1, Mubako T1, Fisher C1., OR    Sarcoma. 2009;2009:741975. doi: 
10.1155/2009/741975. Epub 2009 May 27.Histopathological diagnostic discrepancies in soft tissue 
tumours referred to a specialist centre.Thway K1, Fisher C.   STS pathology is highly complex, and the 
classifications of STS subtypes are constantly evolving. Despite the growing role of molecular 
pathology to facilitate diagnosis, the identification of STS subtypes is still largely reliant on 
interpretation of tumour morphology and immunohistochemistry. Central pathology review 
therefore fulfils an important role in verifying the diagnosis. In contrast to local pathology opinion, 
which may be refined by access to additional tumour samples and clinical and radiological correlates, 
central pathology assessment was wholly dependent on the specimen submitted for review. As STS 
tumours contain areas of heterogeneity, this explains some of the discordance observed between 
local and central pathology opinions.  
The eligibility criteria of previous clinical trials in STS frequently included patients with a variety of 
different histological subtypes. However, as treatments of individual subtypes are progressively 
refined, clinical trials increasingly recruit STS patients with specific histological subtypes. The EORTC 
62043 study, a single-arm phase II trial of pazopanib in patients with advanced STS, for example, 
assessed treatment response in four histological cohorts of STS (leiomyosarcoma, liposarcoma, 
synovial sarcoma and ‘others’) [JCO 2009 27(19):3126-32]. On the basis of this study, patients with 
liposarcoma were excluded from the subsequent phase III PALETTE trial [Lancet Oncol 2012 
379(9829):1879-86]. Different conclusions could be drawn from our subgroup analysis of histological 
subtype as a predictive factor of response to combination chemotherapy, dependent on whether 
local pathology or central pathology assessment of tumour histology was used. This analysis was 
exploratory, and was limited by small numbers of patients in each histological subgroup, but it 
highlights the importance of accurate pathology classification in STS studies, and suggests a role for 
incorporating mandatory prospective central pathology review into future trial protocols. This 
should become practical as shared digital platforms become increasingly common. 
The subgroup analysis suggests that synovial sarcoma, ‘others’ and UPS were most likely to respond 
to treatment with combination chemotherapy. Only UPS by central review classification had 
improved OS  with combination chemotherapy. The lack of OS advantage with combination 
chemotherapy in synovial sarcoma and ‘others’ despite improved tumour response rates is 
consistent with a separate analysis of the EORTC 62012 study, which demonstrated that the absence 
of tumour progression not the extent of disease remission defines prognosis in STS [EJC 2015 
51(S3):S688]. Synovial sarcomas are considered to be chemosensitive tumours. Previous studies 
have suggested synovial sarcomas have higher responses rates to chemotherapy than other STS 
subtypes, including improved response rates to regimens containing ifosfamide [EJC 2010 46:72-78]. 
UPS are aggressive high grade tumours with no discernable histological differentiation [Modern 
Pathology 2014 27:S39-45]. They are diagnosed by exclusion of other pleomorphic subtypes, 
including leiomyosarcoma and liposarcoma. Samples identified as UPS on central pathology review 
therefore include poorly differentiated STS subtypes, which have been re-classified on the basis of 
the submitted specimen. Such poorly differentiated tumours may have aggressive tumour biology 
that benefit more from combination chemotherapy. This would support the parallel observation that 
high grade tumours were more likely to respond to combination chemotherapy than intermediate 
grade lesions, although tumour grade did not influence OS.  
We used central pathology assessment of tumour histology and tumour grade for the predictive  
factor analysis, as this had been undertaken by a small panel of expert sarcoma pathologists. The 
predictive factor analysis identified an improved tumour response rate for liposarcomas compared 
to other STS subtypes. Previous studies have also suggested that liposarcomas are associated with a 
higher response rate (J Clin Oncol 1999 17(1):150-7). Liposarcomas are a group of disparate tumours 
including de-differentiated liposarcoma, pleomorphic liposarcoma and myxoid liposarcoma. Myxoid 
liposarcomas are considered chemosensitive, whilst de-differentiated liposarcomas are considered 
relatively insensitive to chemotherapy. Unfortunately, data were not collected on the proportion of 
liposarcoma subtypes recruited to the EORTC 62012 study.      
PS is a well-established prognostic factor [BJC 2011 104:1544-50]. The EORTC 62012 study recruited 
patients aged ≤60 with WHO PS 0 or 1. It is therefore striking that PS was prognostic of OS despite 
eligibility criteria restricting the study population to young fit patients. Time between initial 
diagnosis of sarcoma and commencing palliative chemotherapy has previously been identified as 
prognostic [JCO 1999 17(1):150-7]. Patients with a shorter time to starting palliative chemotherapy 
from initial diagnosis (3 – 12 months) had worse OS.  This cohort consisted of patients with poor 
tumour biology and rapidly progressive disease. A longer interval between initial diagnosis and 
starting chemotherapy (>12 months) implied less aggressive disease and was associated 
withimproved OS, whilst patients presenting with metastatic disease (interval from initial diagnosis 
<3 months) represented a mix of these two patient populations. The presence of bone metastases 
was the only factor prognostic for OS in the final multivariate model. Bone metastases were 
reported in 44/310 (14.1%) patients included in the subgroup analysis. A previous multi-centre 
retrospective analysis identified bone metastases as a poor prognostic feature, and suggested 
routine use of bisphosphonate therapy for patients with metastatic bone disease to delay the onset 
of skeletal related events (e.g. pathological fracture, spinal cord compression, or hypercalcaemia) 
[ClinCancer Res 2013 3:6]. 
In summary, we performed a subgroup analysis of the EORTC 62012 study, a large phase III trial of 
single-agent doxorubicin versus a doxorubicin-ifosfamide combination for advanced STS. This 
subgroup analysis highlights the importance of the sarcoma pathologist to the assessment of clinical 
trial outcomes. Single-agent doxorubicin remains standard of care first-line chemotherapy for 
patients with advanced soft tissue sarcoma. However, combination doxorubicin-ifosfamide is 
indicated for selected patients, and this analysis suggests combination treatment may be most 
appropriate to consider in young fit patients with high grade, poorly differentiated tumours 
including UPS. 
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